<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GEMCITABINE HYDROCHLORIDE</span><br/>(gem-ci'ta-been)<br/><span class="topboxtradename">Gemzar<br/></span><b>Classifications:</b> <span class="classification">antineoplastic agent</span>; <span class="classification">antimetabolite, pyrimidine</span><br/><b>Prototype: </b>Fluorouracil<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Pyrimidine analog with cell phase specificity by affecting rapidly dividing cells in S phase (DNA synthesis). It also blocks
         the progression of cells from G<sub>1</sub> phase to S phase of cell cycle. Gemcitabine interferes with DNA synthesis by inhibiting ribonucleotide reductase, which results
         in a reduction in the concentration of deoxynucleotides. In addition, if gemcitabine is incorporated into the DNA strand,
         it inhibits further growth of the DNA strand.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Gemcitabine induces DNA fragmentation in cells resulting in the cell death of tumor cells.</p>
<h1><a name="uses">Uses</a></h1>
<p>Locally advanced or metastatic adenocarcinoma of the pancreas.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to gemcitabine, severe thrombocytopenia, acute infection, pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Myelosuppression, renal or hepatic dysfunction, history of bleeding disorders, infection, previous cytotoxic or radiation
         treatment. Safety and effectiveness in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pancreatic Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 1000 mg/m<sup>2</sup> once weekly for up to 7 wk, followed by 1 wk rest from treatment; may repeat once weekly for 3 of every 4 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Dilute with NS without preservatives by adding 5 mL or 25 mL to the 200-mg or 1-g vial, respectively, to yield 40 mg/mL.  <img border="0" src="../images/special/smallsq.gif"/> Shake to dissolve.  <img border="0" src="../images/special/smallsq.gif"/> Dilute further if necessary with NS to concentrations as low as 0.1
                  mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Infuse over 30 min. Infusion time &gt; 60 min is associated with increased toxicity.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted solutions unrefrigerated at 20°25° C (68°77° F). Use within 24 h of reconstitution.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Fever, flu-like syndrome (anorexia, headache, cough, chills, myalgia),</span> paresthesias. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea,</span> stomatitis, <span class="speceff-common">transient elevations of liver transaminases.</span>
<span class="typehead">Hematologic:</span>
<span class="speceff-both">Myelosuppression (anemia, leukopenia, neutropenia, thrombocytopenia)</span>. <span class="typehead">Urogenital:</span> Mild proteinuria and hematuria. <span class="typehead">Other:</span>
<span class="speceff-common">Dyspnea, edema, peripheral edema, infection</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Peak:</span> Peak concentrations reached by 30 min after infusion; lower clearance in women and older adult results in higher concentrations
      at any given dose. <span class="typehead">Distribution:</span> Crosses placenta, distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized intracellularly by nucleoside kinases to active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. <span class="typehead">Elimination:</span> 9298% recovered in urine within 1 wk. <span class="typehead">Half-Life:</span> 3294 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor CBC with differential and platelet count prior to each dose. Monitor baseline and periodic renal and hepatic
            function.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn about common adverse effects and measures to control or minimize when possible. Notify physician immediately of any
            distressing adverse effects.
         </li>
<li>
            							Note: Fever with flu-like symptoms, rash, and GI distress are very common.
            						
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>